The HK1 knockout HCT 116 polyclonal cells constitute a CRISPR/Cas9-edited polyclonal cell population designed to disrupt the expression of the hexokinase 1 (HK1) gene in a human colorectal carcinoma background. This product offers a heterogeneous pool of knockout cells generated by CRISPR/Cas9-mediated gene disruption, providing a loss-of-function model to investigate HK1-dependent processes. The polyclonal format circumvents clonal selection, preserving genetic diversity and enabling the study of gene function in a population context. It is a versatile tool for researchers examining the role of HK1 in glycolysis, mitochondrial physiology, and cancer metabolism.
HCT 116 is an epithelial colorectal carcinoma cell line established from a male patient. It is a widely employed model in colorectal cancer research due to its well-characterized genetic landscape, including mutations in key oncogenes and tumor suppressors that recapitulate human tumor biology. The cell line exhibits a pronounced glycolytic phenotype, characteristic of the Warburg effect, making it particularly suitable for studies on metabolic reprogramming and energy homeostasis. HCT 116 cells are routinely cultured and manipulated using standard techniques, and their robust growth facilitates high-throughput screening and functional genomic investigations.
HK1 encodes one of the four hexokinase isoforms that catalyze the phosphorylation of glucose to glucose-6-phosphate, the rate-limiting first step of glycolysis. This reaction commits glucose to intracellular metabolism and links glycolysis to the pentose phosphate pathway. HK1 is allosterically regulated by glucose-6-phosphate and is transcriptionally regulated by insulin and hypoxia-inducible factor 1-alpha (HIF1A), with additional modulation by AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR) signaling. At the mitochondrial outer membrane, HK1 interacts with voltage-dependent anion channel (VDAC), forming a complex that couples glycolysis to oxidative phosphorylation and influences mitochondrial permeability. Disruption of HK1 by CRISPR/Cas9 impairs glucose phosphorylation, reducing glycolytic flux and altering the association with VDAC. This perturbation can decrease glucose-6-phosphate production, shift metabolic intermediates, and sensitize cells to apoptosis by modulating the BAX/BCL2-regulated mitochondrial apoptotic machinery.
In the HCT 116 context, HK1 knockout profoundly impacts the metabolic profile characteristic of colorectal cancer cells. Given that HCT 116 cells rely heavily on glycolysis for energy production and biosynthetic intermediates, HK1 disruption compromises their ability to sustain rapid proliferation under normoxic or hypoxic conditions. The resulting attenuation of glycolytic flux can unmask vulnerabilities in downstream pathways, such as nucleotide biosynthesis through the pentose phosphate shunt, and may enhance susceptibility to chemotherapeutic agents or targeted therapies. This model therefore provides a valuable platform to dissect the metabolic dependencies of colorectal carcinoma and to explore mechanisms of drug resistance linked to glucose metabolism.
Researchers can employ these polyclonal knockout cells in a wide array of investigative assays. Western blotting and RT-qPCR enable confirmation of HK1 loss and profiling of downstream effectors. Functional studies may include glucose uptake and lactate production assays to measure glycolytic activity, as well as metabolic flux analysis to quantify pathway dynamics. Mitochondrial membrane potential assays and apoptosis detection permit assessment of mitochondrial integrity and cell death induction. The model is particularly suited for exploring the Warburg effect, metabolic reprogramming strategies, and the interplay between glycolysis and apoptotic signaling. It supports drug discovery efforts aimed at glycolysis inhibition and resistance mechanisms. For additional technical information or to discuss customized applications, please contact Ascent Research.
